Comprehensive analysis of tumor immune microenvironment in small cell lung cancer

Comprehensive analysis of tumor immune microenvironment in small cell lung cancer - Tumor immune microenvironment in SCLC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000041056

Enrollment

340

Registered

2020-07-15

Start date

2020-03-15

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small cell lung cancer (SCLC)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Male or female patients 20 years or older Patients with histologically or cytologically confirmed SCLC Patients who received at least dose of cytotoxic agents or ICI

Exclusion criteria

Exclusion criteria: Patients who never received cytotoxic agents or ICI

Design outcomes

Primary

Measure	Time frame
The frequency of SCLC patients characterized by TMB and T-cell inflamed gene expression profile	—

Secondary

Measure	Time frame
The association of the efficacy, OS, PFS, 6 months PFS rate, and ORR of cytotoxic agents as well as ICI and biomarker candidates. The association among biomarker candidates.	—

Countries

Japan

Contacts

Public ContactHiroaki Kanemura

Kindai University, Faulty of Medicine Department of Medical Oncology

hiroaki.kanemura@med.kindai.ac.jp072-366-0221

Outcome results